cd9 antibody (mem-61) biotin Search Results


anti cd9 antibody mem 61  (Novus Biologicals)
91
Novus Biologicals anti cd9 antibody mem 61
Anti Cd9 Antibody Mem 61, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pmc08447189-46-0-9?v=Novus+Biologicals
Average 91 stars, based on 1 article reviews
anti cd9 antibody mem 61 - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
biotinylated cd9  (Novus Biologicals)
92
Novus Biologicals biotinylated cd9
Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of <t>CD9,</t> alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .
Biotinylated Cd9, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd9+antibody+%28mem-61%29+biotin/pmc12832073-156-21-23?v=Novus+Biologicals
Average 92 stars, based on 1 article reviews
biotinylated cd9 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
cd9 antibody mem 61 biotin  (Novus Biologicals)
N/A
The CD9 Antibody MEM 61 Biotin from Novus Biologicals is a mouse monoclonal antibody to CD9 This antibody reacts with human The CD9 Antibody MEM 61 Biotin has been validated for the following applications Western
   Buy from Supplier

Image Search Results


Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .

Journal: Journal of Extracellular Vesicles

Article Title: Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

doi: 10.1002/jev2.70219

Figure Lengend Snippet: Mass spectrometry profiling of extracellular vesicles to reveal putative osimertinib resistance associated networks in mutant EGFR driven non‐small cell lung cancer cells . (A) The size distribution of extracellular vesicles (EVs) isolated from H1975 or H1975/OR cell culture media before and after osimertinib exposure for 48 h are presented with respect to particle size (in nm) and concentration (particles/mL). Average data from three biological replicates is shown. (B) EVs and cell extracts were studied by western blot analysis for expression of CD9, alix and syntenin‐1. Calnexin was used to assess general cellular protein contamination in the EVs samples. Five microgram of protein was loaded from each sample (EVs or cell lysate). (C) The total number of EVs at the time of harvest (48 h post osimertinib treatment) was calculated in three independent biological experiments. One‐way Anova, ∗; p value < 0.05 versus H1975. (D) Volcano plots depicting the mass spectrometry (MS) based protein raw expression values in EVs released from H1975 and H1975/OR cells to cell culture media prior ( top panel ) or post osimertinib ( bottom panel ) treatment. The data are based on the mean of three biological replicates. T ‐test, cutoff: p ≤ 0.05. (E) Protein signatures were filtered out from the MS data using Qlucore software, comparing EVs released from H1975/OR cells or H1975 cells pre‐ and post‐osimertinib treatment. Data are based on three biological replicates. (F) Representation of the obtained StringDB analysis signature of the top proteins found in the EVs from H1975/OR cells presented in (E) .

Article Snippet: Briefly, coverslips were incubated with 1 μg/μL silane‐PEG‐Biotin (Laysian Bio, Inc., AL, USA, cat. #145‐40), blocked with casein and conjugated with biotinylated CD9 (Novus Biologicals, Abingdon, United Kingdom, cat. #NB500‐327B) using a streptavidin linker.

Techniques: Mass Spectrometry, Mutagenesis, Isolation, Cell Culture, Concentration Assay, Western Blot, Expressing, Software